Payment overview · 2025
General Payments
$123.64
6 reported records · 3 companies
Healthcare provider profile · identity verified
Aria Dayani, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BULVERDE, TX · NPI 1366672818
Verified facts
What the public records show
CMS Open Payments records show Aria Dayani, M.D. received $123.64 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 52.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.31 | 52.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.34 | 31.8% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $19.99 | 16.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $123.64 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.34 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.99 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 212 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
212 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 885 | 309 |
| Levothyroxine Sodium | Levothyroxine Sodium | 804 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 683 | 246 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 580 | 194 |
| Lisinopril | Lisinopril | 538 | 195 |
| Metformin Hcl | Metformin Hcl | 519 | 188 |
| Losartan Potassium | Losartan Potassium | 473 | 165 |
| Pantoprazole Sodium | Pantoprazole Sodium | 360 | 117 |
| Meloxicam | Meloxicam | 356 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 122 |
| Hydrochlorothiazide | Hydrochlorothiazide | 336 | 122 |
| Tamsulosin Hcl | Tamsulosin Hcl | 323 | 119 |
| Gabapentin | Gabapentin | 319 | 115 |
| Escitalopram Oxalate | Escitalopram Oxalate | 305 | 106 |
| Omeprazole | Omeprazole | 289 | 104 |
| Carvedilol | Carvedilol | 277 | 92 |
| Trazodone Hcl | Trazodone Hcl | 245 | 93 |
| Azithromycin | Azithromycin | 227 | 196 |
| Montelukast Sodium | Montelukast Sodium | 212 | 84 |
| Mounjaro | Tirzepatide | 212 | 38 |
| Simvastatin | Simvastatin | 211 | 78 |
| Tizanidine Hcl | Tizanidine Hcl | 206 | 106 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 70 |
| Valsartan | Valsartan | 173 | 58 |
| Ezetimibe | Ezetimibe | 169 | 61 |
| Allopurinol | Allopurinol | 168 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 44 |
| Donepezil Hcl | Donepezil Hcl | 163 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 162 | 54 |
| Clonazepam | Clonazepam | 160 | 38 |
| Methylprednisolone | Methylprednisolone | 160 | 127 |
| Furosemide | Furosemide | 159 | 66 |
| Ozempic | Semaglutide | 149 | 37 |
| Buspirone Hcl | Buspirone Hcl | 148 | 56 |
| Glimepiride | Glimepiride | 148 | 57 |
| Bupropion Xl | Bupropion Hcl | 145 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 57 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 127 | 98 |
| Finasteride | Finasteride | 125 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 123 | 38 |
| Sertraline Hcl | Sertraline Hcl | 121 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 51 |
| Metformin Hcl Er | Metformin Hcl | 117 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 35 |
| Prednisone | Prednisone | 109 | 74 |
| Alendronate Sodium | Alendronate Sodium | 108 | 42 |
| Potassium Chloride | Potassium Chloride | 106 | 55 |
| Eliquis | Apixaban | 101 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 100 | 85 |
| Lorazepam | Lorazepam | 97 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 54 |
| Celecoxib | Celecoxib | 94 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 34 |
| Atenolol | Atenolol | 87 | 31 |
| Famotidine | Famotidine | 85 | 30 |
| Alprazolam | Alprazolam | 82 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 82 | 32 |
| Tramadol Hcl | Tramadol Hcl | 80 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 29 |
| Synthroid | Levothyroxine Sodium | 75 | 27 |
| Jardiance | Empagliflozin | 72 | 20 |
| Spironolactone | Spironolactone | 71 | 24 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 69 | 62 |
| Memantine Hcl | Memantine Hcl | 69 | 18 |
| Januvia | Sitagliptin Phosphate | 67 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 20 |
| Propranolol Hcl | Propranolol Hcl | 63 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 63 | 23 |
| Ondansetron Odt | Ondansetron | 60 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 42 |
| Solifenacin Succinate | Solifenacin Succinate | 58 | 22 |
| Estradiol | Estradiol | 57 | 18 |
| Glipizide | Glipizide | 55 | 22 |
| Temazepam | Temazepam | 54 | 11 |
| Pregabalin | Pregabalin | 52 | 17 |
| Aripiprazole | Aripiprazole | 51 | 12 |
| Valacyclovir | Valacyclovir Hcl | 48 | 20 |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 30 |
| Lovastatin | Lovastatin | 46 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 14 |
| Irbesartan | Irbesartan | 43 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 16 |
| Clonidine Hcl | Clonidine Hcl | 41 | 16 |
| Acyclovir | Acyclovir | 40 | 21 |
| Farxiga | Dapagliflozin Propanediol | 38 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 11 |
| Topiramate | Topiramate | 38 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 12 |
| Azelastine Hcl | Azelastine Hcl | 36 | 23 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 13 |
| Mirtazapine | Mirtazapine | 35 | 15 |
| Nifedipine Er | Nifedipine | 35 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | 14 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 15 |
| Armour Thyroid | Thyroid,pork | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 18 |
| Ofloxacin | Ofloxacin | 29 | 28 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 14 |
| Ramipril | Ramipril | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 28 |
| Invokana | Canagliflozin | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 12 |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Euthyrox | Levothyroxine Sodium | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Azathioprine | Azathioprine | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Mupirocin | Mupirocin | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Atacand Hct | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Estrace | Estradiol | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $123.64 · 6 records | Lilly USA, LLC | JARDIANCE, MOUNJARO, QULIPTA, Senza, UBRELVY, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error